Source:http://linkedlifedata.com/resource/pubmed/id/17598007
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2007-6-28
|
pubmed:abstractText |
Heparin treatment may induce osteoporosis by an unknown mechanism. Osteoprotegerin (OPG), a glycoprotein with a heparin-binding site, is a decoy receptor for RANKL which is responsible for osteoclast development. The objective was to investigate the effect of unfractionated heparin (UFH) and lowmolecular-weight heparin (LMWH; dalteparin) on plasma levels of OPG. Twenty-two male students were allocated to the following treatment regimens; A) one bolus of 5,000 IU UFH iv followed by infusion of 450 IU/kg/24 h for 72 hours (n = 7), B) sc administration of LMWH (200 IU/kg) once daily for 72 hours (n = 8), C) sc administration of 100 IU/kg LMWH once (n = 8), D) sc administration of 250 IU/kg UFH once (n = 7), E) control infusion of saline for 12 hours (n = 7). UFH boluses of 5,000 IU were given 4 and 24 hours after cessation of regimens A and B. Bolus injection of UFH iv caused a prompt increase in plasma OPG from 0.68 ng/ml (SD = 0.09) to 1.13 ng/ml (SD = 0.30) (p = 0.003) which declined during the continuous UFH infusion and reached baseline values after 8 hours (regime A). Similar increases in plasma OPG was obtained by repeated UFH boluses after cessation of treatment. Subcutaneous administration of LMWH (200 IU/kg) caused a modest, but significant (p = 0.002) increase in plasma OPG similar to the mobilization by 250 IU/kg UFH sc, but the LMWH treatment caused a three-fold higher anti-Xa activity (p < 0.001). We conclude that UFH causes a more pronounced vascular mobilization of OPG than LMWH, indicating that UFH has a higher affinity for OPG than LMWH.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0340-6245
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
98
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
148-54
|
pubmed:meshHeading |
pubmed-meshheading:17598007-Adult,
pubmed-meshheading:17598007-Blood Circulation,
pubmed-meshheading:17598007-Drug Administration Routes,
pubmed-meshheading:17598007-Heparin,
pubmed-meshheading:17598007-Heparin, Low-Molecular-Weight,
pubmed-meshheading:17598007-Humans,
pubmed-meshheading:17598007-Male,
pubmed-meshheading:17598007-Osteoporosis,
pubmed-meshheading:17598007-Osteoprotegerin,
pubmed-meshheading:17598007-Pharmacokinetics
|
pubmed:year |
2007
|
pubmed:articleTitle |
Heparin induces mobilization of osteoprotegerin into the circulation.
|
pubmed:affiliation |
Center for Atherothrombotic Research in Tromsø (CART), Department of Medicine, Institute of Clinical Medicine, University of Tromsø, N-9037 Tromsø, Norway. anders.vik@fagmed.uit.no
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|